Variable | Control group (n = 70) | Experimental group (n = 77) | Statistical data | P-value |
---|---|---|---|---|
Sexa (n) | 0.242 | 0.623 | ||
Male | 41 | 42 | ||
Female | 29 | 35 | ||
Ageb (years) | 59.36 ± 1.34 | 58.05 ± 1.45 | −0.658 | 0.511 |
BMIb (kg/m2, mean ± SD) | 23.06 ± 0.30 | 23.71 ± 0.29 | 1.568 | 0.119 |
Neoadjuvant therapya (n) | 1.901 | 0.168 | ||
Yes | 8 | 4 | ||
No | 62 | 73 | ||
Tumor sitea (n) | 1.851 | 0.174 | ||
Ileocecal region | 55 | 67 | ||
Near the liver area | 15 | 10 | ||
Tumor size (cm)b (n) | 5.68 ± 1.08 | 5.49 ± 0.88 | −0.97 | 0.334 |
AJCC stage (TNM)a (n) | 1.136 | 0.567 | ||
Period I | 5 | 8 | ||
Period II | 37 | 44 | ||
Period III | 28 | 25 | ||
Preoperative medicationa (n) | 1.009 | 0.604 | ||
Anticoagulants | 11 | 9 | ||
Steroid drugs | 2 | 1 | ||
Other (including none) | 57 | 67 | ||
Underlying diseasesa (n) | ||||
Hypertension | 17 | 16 | 0.259 | 0.611 |
Diabetes | 10 | 7 | 0.968 | 0.325 |
Heart disease | 6 | 12 | 1.678 | 0.195 |
Cerebral infarction | 7 | 8 | 0.006 | 0.938 |